|  |  |  |  |
| --- | --- | --- | --- |
| **Table 1.** Sites of the study | | | |
| ***COUNTRY*** | **CITY** | **HOSPITAL** | **Number of patients per year** |
| *Ecuador* | Quito | Hospital de Especialidades Eugenio Espejo | 200 |
| SOLCA | 100 |
| Instituto de la Tiroides y Enfermedades de Cabeza y Cuello | 100 |
| Guayaquil | SOLCA | 100 |
| Cuenca | SOLCA | 100 |
| Ambato | Hospital Regional Ambato | 100 |
| *Per****u*** | Lima | Hospital Nacional Edgardo Rebagliati Martins | 200 |
| *Uruguay* | Montevideo | Hospital de clínicas Dr. Manuel Quintela | 50 |
| *M****e****xico* | Monterrey | Hospital Universitario “Dr. José E. González”  Universidad Autónoma de Nuevo León | 100 |
| Mexico DF | Clinica de Especialidades | 150 |

**Table 2.** Description of Questionnaire 1

|  |  |
| --- | --- |
| **Questionnaire Items** | **Content** |
| Demographic characteristics | Age, degree of education, region of residence, age at diagnosis, and ethnicity |
| Past Medical Family History | Containing if relatives up to the second degree of consanguinity have had thyroid cancer or thyroid-related diseases. |
| Environmental risk factors | Describe risk factors such as (smoking, medical comorbidities, and radiation) |
| Methods of diagnosis | Describe different diagnostic methods such as ultrasound, FNA, incidental images, and nodules in physical examination. |
| Thyroid gland functionality and description | Describe the last thyroid function recorded in the patient's medical care. |
| Description of thyroid nodule fine-needle aspiration (F.N.A.) | Describe cytological results based on the Bethesda System |

**Table 3.** Description of Questionnaire 2

|  |  |  |
| --- | --- | --- |
| **Sections of the questionnaire** | **Questionnaire items** | **Content** |
| Type of treatment | 2a. Thyroid Surgery | Describe the dates and technical specifications of the proposed treatment in the form. |
| 2b. Radiofrequency ablation | Describe the dates and technical specifications of the proposed treatment in the form. |
| 2c. Active Surveillance | Describe the dates and technical specifications of the proposed treatment in the form. |
| Histological characteristics | Size, histopathology, and nodal, lymphatic, and vascular invasion. | Describe the measures and detailed characteristics |
| Risk of reference calculators | ATA2, E.T.A. 3, and the C.I.L.A. 4 | Describe the measures and detailed characteristics |
| Treatment complications | Hypercalcemia < 6 months and > six months after the procedure, recurrent laryngeal nerve injury, and other complications with active surveillance. | - |

**Table 4.** Description of Questionnaire 3

|  |  |
| --- | --- |
| **Sections of the Questionnaire** | **Content** |
| 1) D.T.C. markers measured after treatment and before medical therapy. | Thyroid-stimulating hormone (TSH), stimulated thyroglobulin (sTg), inhibited thyroglobulin (iTg), and anti-thyroglobulin antibodies (aTg). |
| Description in detail of medical follow-up | Radioactive iodine treatment, its doses, and scan results. |
| Primary outcome (recurrence) | Describe the measures and detailed characteristics |
| Secondary outcomes (response to the treatment, mortality, and quality of life [Q.o.L.]). | Describe the measures and detailed characteristics |

|  |  |  |
| --- | --- | --- |
| **Table 5.** Response to Initial Therapy Definitions | | |
| **Excellent response** | **Acceptable response** | **Incomplete response** |
| All the following   * Suppressed and stimulated Tg < 1 ng/mL * Neck US without evidence of disease * Cross-sectional and/or nuclear medicine imaging negative (if performed) | Any of the following   * Suppressed Tg < 1 ng/mL and stimulated Tg 1 and <10 ng/mL * Neck US with nonspecific changes or stable subcentimeter lymph nodes * Cross-sectional and/or nuclear medicine imaging with nonspecific changes, although not completely normal | Any of the following   * Suppressed Tg 1 ng/mL or stimulated Tg 10 ng/ml * Rising Tg values * Persistent or newly identifies disease on cross-sectional and/or nuclear medicine imaging |